Sugi Predict

Sugi Predict / Compounds / SCHEMBL23930591

SCHEMBL23930591

SCHEMBL23930591

Nc1nc(Nc2ccc(F)c(F)c2)sc1C(=O)c1cc(C(=O)NC2CCCC2)no1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.45
▸ CHRNA7 P36544 3/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ NPC1 O15118 6/20 0.44
▸ RAB9A P51151 6/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ POLB P06746 1/20 0.42
▸ CDK5 Q00535 2/20 0.42
▸ CDK5R1 Q15078 2/20 0.42
▸ LMNA P02545 1/20 0.42
▸ TP53 P04637 1/20 0.42
▸ CCNA2 P20248 2/20 0.41
▸ CDK2 P24941 2/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ S1PR1 P21453 1/20 0.40
▸ MLLT1 Q03111 1/20 0.40
▸ CCNT1 O60563 1/20 0.40
▸ CDK4 P11802 1/20 0.40
▸ CCND1 P24385 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30210963 1.00 MAPT (0.45) MAPTCHRNA7MEN1KMT2ANPC1
SCHEMBL23930636 0.90 CHRNA7 (0.44) MAPTCHRNA7MEN1KMT2APOLB
SCHEMBL30210806 0.90 CHRNA7 (0.44) MAPTCHRNA7MEN1KMT2APOLB
SCHEMBL23930611 0.84 CCNA2 (0.50) MAPTCHRNA7MEN1KMT2ANPC1
SCHEMBL31633457 0.84 CCNA2 (0.50) MAPTCHRNA7MEN1KMT2ANPC1
SCHEMBL23930533 0.83 CHRNA7 (0.46) MAPTCHRNA7MEN1KMT2ANPC1
SCHEMBL30210973 0.83 CHRNA7 (0.46) MAPTCHRNA7MEN1KMT2ANPC1
SCHEMBL23930629 0.81 MAPT (0.52) MAPTCHRNA7MEN1KMT2ANPC1
SCHEMBL23930556 0.81 MAPT (0.52) MAPTCHRNA7MEN1KMT2ANPC1
SCHEMBL23930559 0.81 MAPT (0.52) MAPTCHRNA7MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4139287-B1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AG (DE) 2025-02-26 — — EP disclosed
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 — — US disclosed
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 — — US disclosed
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 — — US disclosed
EP-4139287-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION Bayer Aktiengesellschaft (DE) 2023-03-01 — — EP disclosed
CN-115697979-A Substituted aminothiazoles as DGKZETA inhibitors for immune activation 拜耳公司 2023-02-03 — — CN disclosed
WO-2021214020-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2021-10-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION DGKZ, DGKA, DGKG MAPT 3251/4885CHRNA7 3902/4885MEN1 4290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.